Amphetamine and dextroamphetamine extended-release medications are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy [1][2]. These medications work by affecting the balance of certain natural chemicals in the brain [3].
How do extended-release formulations work?
Extended-release (ER) versions of amphetamine and dextroamphetamine are designed to release the medication gradually over a period of several hours. This controlled release mechanism allows for a longer duration of action compared to immediate-release formulations, typically providing symptom control for up to 10 to 12 hours with a single daily dose [4][5]. This can reduce the need for multiple doses throughout the day, improving patient adherence and potentially offering more consistent symptom management [6].
What are the available extended-release brands?
Several extended-release formulations of amphetamine and dextroamphetamine are available, often marketed under different brand names. These include medications like Adderall XR, Adzenys XR-ODT, and Mydayis [7][8][9]. Each may have slightly different release profiles or administration methods, such as orally disintegrating tablets (ODTs) [8].
When does patent exclusivity expire for these drugs?
Patent exclusivity for amphetamine and dextroamphetamine extended-release products varies by specific formulation and manufacturer. DrugPatentWatch.com tracks these patent expiries, which are crucial for determining when generic versions may enter the market [10]. For example, patents for initial extended-release formulations have expired, allowing for generic competition. However, newer formulations or delivery technologies may have separate and later-expiring patents [10].
Can generic versions of extended-release amphetamine and dextroamphetamine be made?
Once patent protection and any associated market exclusivity periods expire, generic manufacturers can seek approval to produce their own versions of extended-release amphetamine and dextroamphetamine [10]. These generic drugs must be bioequivalent to the brand-name product, meaning they deliver the same amount of active ingredient into the bloodstream over the same period [11]. The availability of generics can significantly reduce the cost of these medications [12].
What are the risks and side effects?
Like all medications, extended-release amphetamine and dextroamphetamine carry potential risks and side effects. Common side effects can include decreased appetite, dry mouth, sleep difficulties, weight loss, and increased heart rate or blood pressure [1]. More serious side effects, though less common, can involve cardiovascular problems, psychiatric issues such as new or worsening psychotic or manic symptoms, and potential for abuse or dependence [1][13]. It is important for patients to discuss their medical history with a healthcare provider to determine if these medications are appropriate and to monitor for any adverse reactions [1][13].
How do these medications compare to alternatives?
Extended-release amphetamine and dextroamphetamine are part of a broader class of ADHD and narcolepsy treatments that include other stimulants and non-stimulant medications [14]. Stimulants like amphetamines are often considered a first-line treatment option due to their efficacy [15]. Non-stimulant options may be considered for individuals who do not respond well to stimulants, experience intolerable side effects, or have contraindications for stimulant use [14]. Comparisons between specific brands and formulations often involve differences in duration of action, onset of effect, and administration methods [4][5][8].
What is the cost and insurance coverage?
The cost of extended-release amphetamine and dextroamphetamine can vary significantly depending on the brand, dosage, and whether a generic version is available [12]. Insurance coverage also plays a substantial role, with many plans covering these medications, often requiring prior authorization or tiered copayments [16]. Patients may also find manufacturer-sponsored discount programs or coupons available for brand-name products [17].
Sources:
[1] https://www.drugs.com/amphetamine-dextroamphetamine.html
[2] https://www.rxlist.com/adderall-xr-drug.htm
[3] https://www.webmd.com/drugs/2/201338/amphetamine-dextroamphetamine-er-oral
[4] https://www.webmd.com/drugs/2/201338/amphetamine-dextroamphetamine-er-oral/details
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120642/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598258/
[7] https://www.drugs.com/imprints/a-54-40-3130.html
[8] https://www.drugs.com/mtm/adzenys-xr-odt.html
[9] https://www.drugs.com/pro/mydayis.html
[10] https://drugpatentwatch.com/
[11] https://www.fda.gov/drugs/generic-drugs
[12] https://www.goodrx.com/amphetamine-dextroamphetamine
[13] https://www.mayoclinic.org/drugs-supplements/amphetamine-dextroamphetamine-oral-route-parenteral-route/proper-use/drg-20061608
[14] https://www.cdc.gov/ncbddd/adhd/treatment.html
[15] https://www.nejm.org/doi/full/10.1056/nejmra1714176
[16] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010455/
[17] https://www.shc.edu/patients-visitors/patient-resources/billing-and-insurance/prescription-assistance